Opportunity To Address Challenges in Achieving a Cure for HBV

NIAID issued a new funding opportunity announcement (FOA), Research to Advance HBV Cure: HIV/HBV Co-Infection and HBV Mono-Infection (R01, Clinical Trial Not Allowed), to fund innovative basic, translational, and clinical research to identify and address challenges to achieving a cure for hepatitis B virus (HBV) infection in the presence or absence of HIV.

We are specifically interested in the following research topics:


  • Investigating how to stimulate HBV-specific innate immune response
  • Investigating how to restore HBV-specific adaptive immune response
  • Studying the impact of HIV/HBV-co-infection on the immunological response to HBV


  • Exploring basic mechanisms of HBV replication or HBV protein expression
  • Elucidating the mechanisms responsible for covalently closed circular DNA (cccDNA) biogenesis, homeostasis, and decay
  • Studying epigenetic regulation of cccDNA transcription
  • Exploring the influence of the host on the HBV life cycle
  • Identifying new viral targets and strategies, including drugs to prevent resistance


  • Developing reproducible cell-free test systems for high-throughput antiviral screening
  • Developing diagnostics that accurately measure cccDNA
  • Developing animal models that resemble HBV infection in humans
  • Identifying biomarkers for various stages of liver injury and viral replication with the goal of clinical care application

For complete details, including a list of studies that we will consider nonresponsive, read the FOA. Remember, the FOA does not support clinical trials.

Application Information

We expect to fund three to five new awards in fiscal year (FY) 2020.  NIAID will commit $4.1 million total for FY 2020.

The maximum project period is five years, although the scope of your proposed project should determine the project period.

NIH’s standard Application Due Dates and standard AIDS and AIDS-Related Applications due dates apply to this FOA. The first non-AIDS-related application due date is February 5, 2019, and the first AIDS-related application due date is May 7, 2019.

Direct your questions to the FOA’s scientific/research divisional contacts:

NOTE: We changed the expiration date for four HBV-related FOAs—NOT-AI-19-018, NOT-AI-19-019, NOT-AI-020, NOT-AI-021. The last date that NIAID and its co-participants will accept applications for these FOAs is January 7, 2019, or for applicants eligible for continuous submission, February 7, 2019.

Content last reviewed on

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.